HEM PharmaHEM파마
376270 · KOSDAQ · ₩376270 · HEM파마
₩26,200▲ ₩50 (0.19%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩13B | ₩15B | ₩5.3B | ₩3.7B | ₩1.9B |
| Cost of sales | ₩12B | ₩13B | ₩4.5B | ₩3B | ₩1.4B |
| Gross profit | ₩632M | ₩1.6B | ₩801M | ₩623M | ₩487M |
| Operating income | −₩16B | −₩7.7B | −₩12B | −₩13B | −₩11B |
| Net income | −₩24B | −₩7.6B | −₩12B | −₩13B | −₩11B |
| Net income to shareholders | −₩24B | −₩7.6B | −₩12B | −₩13B | −₩11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩52B | ₩37B | ₩28B | ₩35B | ₩27B |
| Current assets | ₩23B | ₩17B | ₩11B | ₩23B | ₩16B |
| Cash and equivalents | ₩14B | ₩6.3B | ₩8.2B | ₩2.2B | ₩11B |
| Total liabilities | ₩47B | ₩11B | ₩10B | ₩15B | ₩5.7B |
| Current liabilities | ₩40B | ₩9.1B | ₩8.6B | ₩14B | ₩1.5B |
| Borrowings | ₩17B | ₩6.5B | ₩6.5B | ₩12B | ₩3.3B |
| Total equity | ₩5.2B | ₩26B | ₩17B | ₩20B | ₩21B |
| Shareholders' equity | ₩5B | ₩26B | ₩17B | ₩20B | ₩21B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩8.3B | −₩7.7B | −₩5.3B | −₩11B | −₩7.5B |
| Capital spending | −₩9.8B | ₩4.7B | ₩4.5B | ₩10B | ₩6.8B |
| Free cash flow | −₩18B | −₩12B | −₩9.8B | −₩21B | −₩14B |
Consolidated where available. Amounts in won.
Also known as: HEM Pharma / HEM파마 / 376270 / KRX:376270
Source: KRX statistical information